Capivasertib + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced (Inoperable) or Metastatic Breast Cancer
Conditions
Locally Advanced (Inoperable) or Metastatic Breast Cancer
Trial Timeline
May 10, 2021 → Aug 14, 2029
NCT ID
NCT04862663About Capivasertib + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib
Capivasertib + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib is a phase 3 stage product being developed by AstraZeneca for Locally Advanced (Inoperable) or Metastatic Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04862663. Target conditions include Locally Advanced (Inoperable) or Metastatic Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04862663 | Phase 3 | Recruiting |
Competing Products
20 competing products in Locally Advanced (Inoperable) or Metastatic Breast Cancer